Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-09T07:34:39.028Z Has data issue: false hasContentIssue false
  • English
  • Français

Decision Analysis: A Tool for Infection Control

Published online by Cambridge University Press:  09 April 2017

Mary D. Nettleman
Mary D. Nettleman*
Affiliation:
Division of Clinical Epidemiology Department of Internal Medicine, The University of Iowa Hospital:s and Clinics, Iowa City, Iowa
*
Division of Clinical Epidermolgy, C41 GH, The University of Iowa Hospitals and Clinics, Iowa City, IA 52242
Get access Rights & Permissions [Opens in a new window]

Extract

Financial resources for health care have been restricted. Constraints demand that physicians and administrators get the most for their money, yet the myriad of diagnostic tests and antibiotics available today can easily boggle the minds of those who must choose among them. This situation is particularly true of infection control where active research continually produces new products. Each hospital must choose among disinfectants, detergents, antibiotics, protective clothing, immunizations, dressing supplies, respiratory therapies, and many other products. At every point, questions arise. Is a new product worth the extra money? Alternatively, is a less expensive product really more cost-effective? How many additional infections must be prevented before a product “pays” for itself?

Type
Special Sections
Information
Infection Control & Hospital Epidemiology , Volume 9 , Issue 2 , February 1988 , pp. 88 - 91
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Weinstein, MC, Fineberg, HV: Clinical Decision Analysis. Philadelphia, WB Saunders Co, 1980.Google Scholar
2.Pauker, SG, Kassirer, JP: Decision analysis. N Engl J Med 1987; 316:250–258.CrossRefGoogle ScholarPubMed
3.Kassirer, JP, Moskowitz, AJ, Lau, J, et al: Decision analysis: A progress report. Ann Intern Med 1987; 106:275–291.CrossRefGoogle ScholarPubMed
4.Nettleman, MD, Jones, RB, Roberts, SD, et al: Cost-effectiveness of culturing patients attending a sexually transmitted diseases clinic for Chlamydia trachomatis. Ann Intern Med 1986; 105:189–193.Google Scholar
5.Nettleman, MD, Jones, RB. Roberts, SD, et al: Cost-effectiveness of serology and cell culture for Chlamydia trachomatis in low prevalence women, in Oriel, D, Ridgway, G, Schachter, J, et al (eds): Chlamydial Infections. Cambridge, England. Cambridge University Press, 1986, pp 205–208.Google Scholar
6.Van Herle, AJ. Rich, P, Ljung, BE, et al: The thyroid nodule. Ann Intern Med 1982; 96:221–232.CrossRefGoogle Scholar
7.Koplan, JP, Schoenbaum, SC, Weinstein, MC, et al: Pertussis vaccine-An analysis of benefits, risks and costs. N Engl J Med 1979; 301:906–911.CrossRefGoogle ScholarPubMed
8.Rose, DN, Schechter, CB, Silver, AL: The age threshold for isoniazid chemoprophylaxis: A decision analysis for low-risk tuberculin reactors. JAMA 1986; 256:2709–2713.CrossRefGoogle ScholarPubMed
9.Binkin, NJ, Koplan, JP, Cates, W Jr: Preventing neonatal herpes: The value of weekly viral cultures in pregnant women with recurrent genital herpes. JAMA 1984; 251:2816–2821.Google Scholar
10.Ransohoff, DF, Gracie, WA, Wolfenson, LB, et al: Prophylactic cholecystectomy or expectant management for silent gallstones: A decision analysis to assess survival. Ann Intern Med 1983; 99:199–204.CrossRefGoogle ScholarPubMed
11.Mulley, AG, Silverstein, MD, Dienstag, JL: Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis. Med Decis Making 1981; 1:40–43.Google Scholar